Surrozen (NASDAQ:SRZN) VP Yang Li Sells 1,118 Shares

Surrozen, Inc. (NASDAQ:SRZN) VP Yang Li sold 1,118 shares of the business’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $19.87, for a total value of $22,214.66. Following the completion of the sale, the vice president directly owned 16,091 shares in the company, valued at $319,728.17. This represents a 6.50% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Surrozen Stock Up 3.0%

Shares of Surrozen stock opened at $19.67 on Wednesday. The business has a fifty day simple moving average of $17.64 and a 200-day simple moving average of $13.39. Surrozen, Inc. has a fifty-two week low of $5.90 and a fifty-two week high of $24.94. The firm has a market cap of $168.57 million, a price-to-earnings ratio of -0.88 and a beta of 0.58.

Surrozen (NASDAQ:SRZN) last issued its quarterly earnings results on Friday, November 7th. The company reported ($3.61) EPS for the quarter, missing the consensus estimate of ($1.17) by ($2.44). Surrozen had a negative return on equity of 4,055.04% and a negative net margin of 2,909.10%.The business had revenue of $0.98 million during the quarter. Analysts anticipate that Surrozen, Inc. will post -8.49 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently weighed in on SRZN shares. Weiss Ratings restated a “sell (d-)” rating on shares of Surrozen in a report on Wednesday, October 8th. Wall Street Zen upgraded Surrozen to a “sell” rating in a research report on Friday, November 28th. Finally, Lifesci Capital upgraded Surrozen to a “strong-buy” rating in a report on Thursday, November 13th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $32.00.

Institutional Trading of Surrozen

Several large investors have recently added to or reduced their stakes in the company. Citadel Advisors LLC raised its position in Surrozen by 32.8% during the third quarter. Citadel Advisors LLC now owns 13,875 shares of the company’s stock valued at $179,000 after buying an additional 3,424 shares during the period. Geode Capital Management LLC grew its stake in Surrozen by 22.6% during the 2nd quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock valued at $277,000 after acquiring an additional 5,702 shares in the last quarter. Armistice Capital LLC acquired a new stake in shares of Surrozen during the second quarter worth approximately $536,000. Woodline Partners LP acquired a new stake in shares of Surrozen during the third quarter worth approximately $621,000. Finally, Schonfeld Strategic Advisors LLC purchased a new position in Surrozen during the third quarter valued at approximately $889,000. 66.57% of the stock is owned by institutional investors and hedge funds.

About Surrozen

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.